Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Janet Tsang

Clinical Cardiac Electrophysiology Baltimore, MD Medical Doctor

NPI 1306038187 CMS profile 1386156

5601 Loch Raven Blvd, Russell Morgan Bldg, Ste 206, Baltimore, MD 21239

Open in the dashboard

General payments

$20,530

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janet Tsang of Baltimore, MD is reported in the CMS Open Payments database as having received $20,530 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79 4
2024 General $61 3
2022 General $13 1
2021 General $61 3
2020 General $5,145 36
2019 General $15,171 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janet Tsang
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Janet Tsang were reported at $79. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Janet Tsang Clinical Cardiac Electrophysiology median Middle half National median
2019 $15,171 $2,361 $585–$8,260 $163
2020 $5,145 $993 $247–$4,351 $114
2021 $61 $1,185 $326–$4,739 $132
2022 $13 $2,073 $554–$6,789 $149
2023 $0 $2,568 $759–$8,159 $160
2024 $61 $2,557 $703–$7,403 $164
2025 $79 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $9,292 48 payments
  2. Boston Scientific Corporation $8,849 10 payments
  3. Abbott Laboratories $1,971 25 payments
  4. Medical Device Business Services, Inc. $145 3 payments
  5. Lantheus Medical Imaging, Inc. $122 6 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $94 1 payment
  7. Edwards Lifesciences Corporation $26 1 payment
  8. Philips Electronics North America Corporation $18 1 payment
  9. Novartis Pharmaceuticals Corporation $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $12,317 4 payments
  2. Travel and Lodging $3,863 18 payments
  3. Food and Beverage $3,711 70 payments
  4. Education $639 4 payments
Products named General payments · program years 2019–2025
  1. GENERAL BRADY $6,750 2 payments
  2. GENERAL - BRADY $1,400 1 payment
  3. Agilis NxT EP Introducer $690 3 payments
  4. General Therapies $664 5 payments
  5. Ensite Cardiac Mapping System $590 7 payments
  6. EnSite Velocity System Mapping D $466 4 payments
  7. Carto 3 System $145 3 payments
  8. Quadra Assura CRT Defibrillator $135 5 payments
  9. DEFINITY $122 6 payments
  10. LifeVest $94 1 payment
  11. Other $211 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,033

Median for Cardiology: 2,533

Drug cost

$332,095

Median for Cardiology: $485,213

Branded share of claims

28.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 118 $145,548
Entresto Sacubitril/Valsartan Brand 57 $92,907
Jardiance Empagliflozin Brand 34 $50,461
Xarelto Rivaroxaban Brand 20 $30,273
Metoprolol Succinate Generic 127 $2,259
Atorvastatin Calcium Generic 98 $1,646
Rosuvastatin Calcium Generic 33 $1,490
Carvedilol Generic 112 $1,113
Ezetimibe Generic 20 $1,053
Amiodarone Hcl Generic 35 $786

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$162,619

Of which drugs: $703

Medicare patients

815

Average age 75

Services billed

1,975

484 women, 331 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 54%
Diabetes 52%
Heart failure 48%
Chronic kidney disease 47%
Atrial fibrillation 38%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 22 88 $604
Injection, aminophyllin, up to 250 mg J0280 Office 12 17 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DEFINITY
  • Lantheus Medical Imaging, Inc. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record